MNKD vs RARE · rev $199.5M vs rev $350.0M
MannKind Corp (MNKD) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
MannKind Corp (MNKD) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported MNKD revenue for 2026-06-30 was $199.5M. Net income was -$35.7M. MNKD currently screens at market cap $1.28B.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
MNKD currently screens at market cap $1.28B. RARE currently screens at market cap $2.79B.
Not investment advice. Open the MNKD and RARE stock pages for the full models.
Not investment advice.